Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Recruiting in Palo Alto (17 mi)

+119 other locations

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Avanir Pharmaceuticals

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called AVP-786 to see if it can help people with schizophrenia who have negative symptoms like lack of motivation and social withdrawal. The study will compare AVP-786 to another group to check its benefits.

Research Team

Eligibility Criteria

Inclusion Criteria

Participants who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) diagnostic criteria for schizophrenia confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) Version 7.0.2

Participants must have well-controlled positive symptoms and prominent negative symptoms as defined by Positive and Negative Syndrome Scale (PANSS) criteria.

Participants currently receiving a second-generation atypical antipsychotic drug (SGA) are eligible if they are stable and adherent to their dosing schedule.

See 1 more

Exclusion Criteria

Participants with pseudo-parkinsonism secondary to their ongoing antipsychotic medication

Participants currently using anticholinergic medications

Participants recently hospitalized as in-patients

See 1 more